Business Description
Surrozen Inc
NAICS : 541714
SIC : 2833
ISIN : US86889P2083
Share Class Description:
SRZN: Ordinary SharesTotal Employee Number:
44Description
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 15.77 | |||||
Equity-to-Asset | -2.3 | |||||
Debt-to-Equity | -0.02 | |||||
Debt-to-EBITDA | -0.16 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -15.46 | |||||
Beneish M-Score | -1.24 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -55.8 | |||||
3-Year EBITDA Growth Rate | 32.8 | |||||
3-Year EPS without NRI Growth Rate | 17.5 | |||||
3-Year FCF Growth Rate | 40.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 54.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -45.97 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.46 | |||||
9-Day RSI | 36.02 | |||||
14-Day RSI | 40.22 | |||||
3-1 Month Momentum % | -20.21 | |||||
6-1 Month Momentum % | 8.55 | |||||
12-1 Month Momentum % | 149.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.91 | |||||
Quick Ratio | 11.91 | |||||
Cash Ratio | 11.18 | |||||
Days Sales Outstanding | 143.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -69.5 | |||||
Shareholder Yield % | -13.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -573.75 | |||||
Net Margin % | -4571.14 | |||||
EBITDA Margin % | -569.64 | |||||
FCF Margin % | -449.44 | |||||
OCF Margin % | -446.49 | |||||
ROA % | -322.56 | |||||
ROIC % | -451.21 | |||||
3-Year ROIIC % | -102.56 | |||||
ROC (Joel Greenblatt) % | -636.41 | |||||
ROCE % | -43.99 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 30.7 | |||||
EV-to-EBIT | -3.85 | |||||
EV-to-EBITDA | -3.88 | |||||
EV-to-Revenue | 22.09 | |||||
EV-to-Forward-Revenue | 33.45 | |||||
EV-to-FCF | -4.91 | |||||
Earnings Yield (Greenblatt) % | -25.97 | |||||
FCF Yield % | -12.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SRZN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Surrozen Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.494 | ||
| EPS (TTM) ($) | -41.34 | ||
| Beta | 1.3017 | ||
| 3-Year Sharpe Ratio | 0.8 | ||
| 3-Year Sortino Ratio | 1.49 | ||
| Volatility % | 53.94 | ||
| 14-Day RSI | 40.22 | ||
| 14-Day ATR ($) | 2.021127 | ||
| 20-Day SMA ($) | 23.894 | ||
| 12-1 Month Momentum % | 149.58 | ||
| 52-Week Range ($) | 8.2001 - 35 | ||
| Shares Outstanding (Mil) | 11.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Surrozen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Surrozen Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 16:06 | In 30 days | ||
| H.C. Wainwright 4(th) Annual BioConnect Investor Conference | 2026-05-19 11:30 | 27.44 (-2.42%) | ||
| General meeting for 2026 | 2026-05-13 10:00 | 30.66 (+4.64%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 32.64 (-0.64%) | ||
| Annual report for 2025 | 2026-03-23 | 25.15 (-6.23%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 25.15 (-6.23%) | ||
| TD Cowen 46(th) Annual Healthcare Conference | 2026-03-04 13:10 | 26.85 (-5.16%) | ||
| Guidance call for 2026 | 2026-02-12 13:30 | 24.60 (+6.54%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-03 15:25 | 15.54 (-3.12%) |
Show
Entries
Surrozen Inc Frequently Asked Questions
What is Surrozen Inc(SRZN)'s stock price today?
The current price of SRZN is $22.88. The 52 week high of SRZN is $35.00 and 52 week low is $8.20.
When is next earnings date of Surrozen Inc(SRZN)?
The next earnings date of Surrozen Inc(SRZN) is 2026-08-07 Est..
Does Surrozen Inc(SRZN) pay dividends? If so, how much?
Surrozen Inc(SRZN) does not pay dividend.
Guru Commentaries on NAS:SRZN
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Surrozen Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers